Bristol Myers Squibb (CELG-RI) Return on Assets (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Return on Assets of 0.0% for Q2 2026, little changed year-over-year from 0.0% in Q2 2025, and up 29.3% quarter-over-quarter from 0.0% in Q1 2026.
Bristol Myers Squibb (CELG-RI) Return on Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Return on Assets for 17 consecutive years, with 0.0% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Assets changed 0.0% year-over-year to 0.0%; the TTM figure through Jun 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
- Return on Assets rose to 0.0% in Q2 2026 per CELG-RI's latest filing, from 0.0% in the prior quarter.
- Across five years, Return on Assets topped out at 0.0% in Q2 2026 and bottomed at 0.0% in Q4 2024.
- Historically, Return on Assets has averaged 0.0% across 5 years, with a median of 0.0% in 2022.
- On a YoY basis, Return on Assets climbed as much as 0 bps in 2022 and fell as far as 0 bps in 2022.
- Bristol Myers Squibb's Return on Assets stood at 0.0% in 2022, then surged by 33 bps to 0.0% in 2023, then tumbled by 211 bps to 0.0% in 2024, then soared by 179 bps to 0.0% in 2025, then jumped by 41 bps to 0.0% in 2026.
- Business Quant data shows CELG-RI's Return on Assets at 0.0% in Q2 2026, 0.0% in Q1 2026, and 0.0% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 648.02 Bn | 627.27 Bn | 17.26 Bn | 0.00% |
| 2 | AbbVie | 467.00 Bn | 460.43 Bn | 12.70 Bn | 0.00% |
| 3 | Merck | 373.58 Bn | 366.43 Bn | 12.21 Bn | 0.00% |
| 4 | Novartis Ag | 299.43 Bn | 291.74 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 256.09 Bn | 251.19 Bn | 12.86 Bn | 0.00% |
| 6 | Amgen | 235.35 Bn | 221.36 Bn | 7.24 Bn | 0.00% |
| 7 | Gilead Sciences | 179.91 Bn | 176.73 Bn | 6.22 Bn | 0.00% |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | 0.00% |
| 9 | Gsk | 104.91 Bn | 100.74 Bn | 8.24 Bn | 0.00% |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00% |
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | 0.00% |